Ruxolitinib May Prove Beneficial in Combination for Myelofibrosis

In a presentation at the 2018 Society of Hematologic Oncology Annual Meeting, Robyn M. Scherber, MD, MPH, of the Mays Cancer Center at UT Health San Antonio MD Anderson, discussed the potential benefit of ruxolitinib combination therapies (eg, hypomethylating agents, immunotherapies, targeted therapies) for the treatment of myelofibrosis in patients who have become refractory or resistant to ruxolitinib.

 Targeted Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.